|Videos|January 3, 2023

Expert discusses what is on the horizon for stone disease in coming years

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

In this interview, Thomas Chi, MD, predicts what might be on the horizon for stone disease in the coming years, and he discusses some of his own research interests within the field. Chi is a professor and associate chair at the University of California, San Francisco.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

November 12th, 2026

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing

The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.

November 11th, 2026

Q&A: Ronald Anglade, MD, on genetic testing in male infertility

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

November 11th, 2026

BCG-naïve NMIBC: Optimizing initial treatment selection

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

November 11th, 2026

Survey: Service members and veterans with NMIBC report barriers to treatment access

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.

November 10th, 2026

Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

November 10th, 2026

FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection

Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.

November 9th, 2026

Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study

Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.

November 9th, 2026

Nogapendekin alfa inbakicept plus BCG meets primary end point in BCG-naïve NMIBC

The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.

Expert discusses what is on the horizon for stone disease in coming years

Related to this article

Trending on Urology Times

FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection

Survey: Service members and veterans with NMIBC report barriers to treatment access

BCG-naïve NMIBC: Optimizing initial treatment selection

Q&A: Ronald Anglade, MD, on genetic testing in male infertility

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing